What is Haemonetics's market cap?

Haemonetics (HAE) has a market capitalization of $3.6B and trades on NYSE.

What is Haemonetics's revenue and profitability?

Haemonetics generated $1.3B in trailing twelve-month revenue, representing a net margin of 13.3%. Gross margin stands at 59.0%, with free cash flow of $260.4M. These figures are based on the Q1 2026 filing.

Who are Haemonetics's competitors?

Haemonetics's key competitors include Teleflex, Cytosorbents Corp., Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Who does Haemonetics partner with?

Haemonetics's notable partners include American Red Cross.

What subsidiaries does Haemonetics have?

Haemonetics's subsidiaries include OpSens Inc., Attune Medical, Vivasure Medical Limited.

Where is Haemonetics headquartered?

Haemonetics is headquartered in United States of America and employs approximately 3,657 people. It has been publicly traded since 1991.

Haemonetics

HAE

Haemonetics is a global medical technology company that provides innovative solutions for blood and plasma collection, surgical blood management, and interventional procedures.

Market cap

$3.63B-0.4%

Revenue$1.3B-2.0%

Free cash flow$260.4M+82.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q4 2026 report

May 7, 2026

Revenue$346.4MBeat by $9.5M EPS$1.29Beat by $0.01

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$327.9M

EPS estimate$1.07

Financials

Q4 2026

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation & ratios

Valuation

See full

Market cap$3.63B-0.4%

Enterprise value$4.66B+3.1%

P/S2.7×+0.1×

Profitability

See full

Gross margin59%+4.0pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Segments

By segment

See full

Hospital$159.6M+8.0%

Plasma$130.3M+2.8%

Blood Center$56.4M+0.7%

By geography

See full

Europe$52.9M+25.1%

Rest of Asia$20.0M-5.6%

Other$3.1M+12.3%

By product

See full

Plasma$130.3M+2.8%

Competitors

By market cap

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Boston Scientific$67.6B-56.8%

TFX

Teleflex$5.8B+13.6%

LivaNova$4.4B+86.8%

Haemonetics$3.6B+1.2%

InfuSystem Holdings$188.9M+52.6%

Cytosorbents$22.6M-61.6%

By revenue growth

TFX

Teleflex+25.0%

Boston Scientific+13.5%

LivaNova+12.4%

Medtronic+8.4%

Abbott+8.1%

InfuSystem Holdings+3.5%

Haemonetics-2.0%

By net margin

Boston Scientific17.48%+4.0pp

Haemonetics13.31%—

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

InfuSystem Holdings5.56%+3.2pp

LivaNova-16.12%-22.5pp

TFX

Teleflex-47.43%-56.2pp

Profile

Haemonetics is a global medical technology company that provides innovative solutions for blood and plasma collection, surgical blood management, and interventional procedures. The company's core value proposition centers on improving healthcare efficiency and patient outcomes through automated collection systems, specialized surgical devices, and integrated information technology platforms.

Competitive position

A global leader in automated plasma collection and advanced viscoelastic testing, maintaining a strong market position in vascular closure and blood management technologies.

GeographiesNorth America, Europe, Asia Pacific, Global

Customer segmentsBiopharmaceutical manufacturers, Hospitals, Blood banks, Surgical centers

Business modelManufacturing, Hardware-as-a-Service, Software-as-a-Service, Consumables-driven revenue

SuppliersContract manufacturers for capital equipment, Raw material suppliers (plastics and components), Sterilization service providers

CustomersBiopharmaceutical companies (fractionators), Hospital systems, Blood collection organizations, Group purchasing organizations

CountryUnited States of America

Listed1991

Employees3.7K

CEOChristopher A. Simon

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitehaemonetics.com

FilingsSEC EDGAR

Ask your AI about Haemonetics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's market cap?: Haemonetics (HAE) has a market capitalization of $3.6B and trades on NYSE.
What is Haemonetics's revenue and profitability?: Haemonetics generated $1.3B in trailing twelve-month revenue, representing a net margin of 13.3%. Gross margin stands at 59.0%, with free cash flow of $260.4M. These figures are based on the Q1 2026 filing.
Who are Haemonetics's competitors?: Haemonetics's key competitors include Teleflex, Cytosorbents Corp., Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does Haemonetics partner with?: Haemonetics's notable partners include American Red Cross.
What subsidiaries does Haemonetics have?: Haemonetics's subsidiaries include OpSens Inc., Attune Medical, Vivasure Medical Limited.
Where is Haemonetics headquartered?: Haemonetics is headquartered in United States of America and employs approximately 3,657 people. It has been publicly traded since 1991.